Suven Pharmaceuticals
- Advice
- Hold
Suven Pharmaceuticals Performance
Day Range
- Low 643.20
- High 671.45
52 Week Range
- Low 450.50
- High 671.45
- Open Price652.75
- Previous Close649.40
- Volume509064
Start SIP in Suven Pharmaceuticals
Start SIPSuven Pharmaceuticals Investment Rating
-
Master Rating:
-
Suven Pharmaceuticals has an operating revenue of Rs. 1,301.73 Cr. on a trailing 12-month basis. An annual revenue de-growth of -2% needs improvement, Pre-tax margin of 42% is great, ROE of 23% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 13% and 28% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 8% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 70 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 225 | 344 | 364 | 348 | 278 | 339 | 364 |
Operating Expenses Qtr Cr | 127 | 174 | 190 | 201 | 172 | 184 | 206 |
Operating Profit Qtr Cr | 97 | 170 | 175 | 147 | 107 | 155 | 158 |
Depreciation Qtr Cr | 10 | 11 | 11 | 11 | 11 | 11 | 10 |
Interest Qtr Cr | 1 | 1 | 2 | 1 | 0 | 1 | 2 |
Tax Qtr Cr | 26 | 43 | 42 | 38 | 27 | 40 | 55 |
Net Profit Qtr Cr | 75 | 124 | 130 | 109 | 79 | 114 | 224 |
Suven Pharmaceuticals Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹598.33
- 50 Day
- ₹573.95
- 100 Day
- ₹548.27
- 200 Day
- ₹522.46
- 20 Day
- ₹589.11
- 50 Day
- ₹574.00
- 100 Day
- ₹537.66
- 200 Day
- ₹507.12
Suven Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 670.13 |
Second Resistance | 684.92 |
Third Resistance | 698.38 |
RSI | 76.22 |
MFI | 91.20 |
MACD Single Line | 10.87 |
MACD | 18.17 |
Support | |
---|---|
First Resistance | 641.88 |
Second Resistance | 628.42 |
Third Resistance | 613.63 |
Suven Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 529,340 | 20,024,932 | 37.83 |
Week | 670,798 | 26,798,380 | 39.95 |
1 Month | 348,766 | 17,326,674 | 49.68 |
6 Month | 486,231 | 31,634,208 | 65.06 |
Suven Pharmaceuticals Result Highlights
Suven Pharmaceuticals Synopsis
NSE-Medical-Generic Drugs
Suven Pharmaceutical is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1330.08 Cr. and Equity Capital is Rs. 25.46 Cr. for the Year ended 31/03/2023. Suven Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 06/11/2018 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24299TG2018PLC128171 and registration number is 128171.Market Cap | 16,683 |
Sales | 1,282 |
Shares in Float | 10.18 |
No of funds | 154 |
Yield | 0.18 |
Book Value | 9.54 |
U/D Vol ratio | 2.9 |
LTDebt / Equity | 2 |
Alpha | 0.15 |
Beta | 0.07 |
Suven Pharmaceuticals
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 60% | 60% | 60% | 60% |
Mutual Funds | 12.15% | 9.12% | 8.56% | 8.97% |
Insurance Companies | 1.38% | 0.11% | 2.26% | 2.23% |
Foreign Portfolio Investors | 10.01% | 9.5% | 9.47% | 8.11% |
Financial Institutions/ Banks | ||||
Individual Investors | 11.76% | 12.8% | 12.76% | 14.01% |
Others | 4.7% | 8.47% | 6.95% | 6.68% |
Suven Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Venkateswarlu Jasti | Managing Director |
Ms. Deepanwita Chattopadhyay | Independent Director |
Dr. Jerry Jeyasingh | Non Exe.Non Ind.Director |
Mr. J V Ramudu | Chairman, Non Ind & Non Exe Director |
Mr. D G Prasad | Independent Director |
Dr. V Sambasiva Rao | Independent Director |
Suven Pharmaceuticals Forecast
Price Estimates
Suven Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-09 | Quarterly Results | |
2023-08-08 | Quarterly Results | |
2023-05-25 | Audited Results | |
2023-02-06 | Quarterly Results | |
2022-11-08 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2022-09-12 | INTERIM | Rs.1.00 per share(100%)Interim Dividend |
2022-09-12 | SPECIAL | Rs.5.00 per share(500%)Special Dividend |
2022-05-17 | INTERIM | Re.1.00 per shaer (100%) Second Interim Dividend |
2022-05-17 | SPECIAL | Rs.1.00 per share(100%)Special Dividend |
2022-02-16 | INTERIM | Rs.1.00 per share(100%)Interim Dividend |
Suven Pharmaceuticals FAQs
What is Share Price of Suven Pharmaceuticals ?
Suven Pharmaceuticals share price is ₹655 As on 30 November, 2023 | 06:55
What is the Market Cap of Suven Pharmaceuticals ?
The Market Cap of Suven Pharmaceuticals is ₹16682.9 Cr As on 30 November, 2023 | 06:55
What is the P/E ratio of Suven Pharmaceuticals ?
The P/E ratio of Suven Pharmaceuticals is 38.6 As on 30 November, 2023 | 06:55
What is the PB ratio of Suven Pharmaceuticals ?
The PB ratio of Suven Pharmaceuticals is 9.6 As on 30 November, 2023 | 06:55